NCT03179436: Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)

NCT03179436
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Known untreated central nervous system (CNS) metastases or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03179436

Comments are closed.

Up ↑